UM: Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

UM: Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

An international phase III clinical trial evaluating the drug Arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) has reached full enrollment, as reported by a University of Miami Miller School of Medicine researcher. The current phase III trial builds upon the results of a prior phase II trial that enrolled patients with a rapidly progressive, rare genetic form of ALS.

Full Story

Related posts

FIU Researchers deploy new tech to explore depths of Gulf of Mexico

FIU marine scientist Kevin Boswell and a multi-institution research team will deploy experimental technology next…

USF Health Neurology and VuEssence collaborate on stroke early-detection test

The diagnostic blood test being developed is intended to speed treatment critical to improving ischemic…

No visits? No problem: FSU researchers find incarcerated juveniles still optimistic about future

A new study by Florida State University researchers taps into the vastly unexplored area of…